Plain-English translation of NCT07090759 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called (also known as Neracorvir) for people with chronic hepatitis B who are not responding well enough to their current antiviral medications. The medication would be added on top of the drugs you're already taking. Researchers want to see if this addition helps control the virus better and is safe to use.
Some people with hepatitis B continue to have detectable virus in their blood even while taking standard antiviral medications. This trial exists to find out whether this medication can help those patients achieve better control of their hepatitis B when added to their current treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication or a placebo (a pill with no active drug) added to your current hepatitis B treatment. You will continue taking your regular antiviral medication throughout the study. The trial involves visits to the clinic where researchers will monitor your health, check your virus levels, and watch for any side effects. The study includes 526 patients across multiple centers, and you would be one of approximately 263 people in either the medication or placebo group.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China